Home › Research › What the research found › Every row
Every row of the evidence table
One row per finding: what was tested, which way the result went, and how the study was built. The answer by area, and where the studies disagree, are on the main page.
Every row
Filter
Showing 3 of 382 rows. One row per study per exposure: a study that tested two different things appears twice, once for each.
Scroll the table sideways to see every column.
| Exposure | Question | Direction | Outcome measured | Design | People | Effect size, as the source reported it | Source |
|---|---|---|---|---|---|---|---|
| Antihypertensives / BP lowering Medicines | Prevention |
Benefit
whyIndividual participant data from five double-blind placebo-controlled trials, which is the strongest design in this table for this exposure. |
Incident dementia over a median 4.3 years | meta-analysis | 28,008 | Adjusted OR 0.87 (95% CI 0.75-0.99) for incident dementia |
European Heart Journal
2022 ✓ Peer-reviewed PMID 36282295 |
| Antihypertensives / BP lowering Medicines | Prevention |
Benefit
whyConsistent across 14 trials (I-squared 0%) but small in absolute terms: 0.39 percentage points over about 4 years. |
Incident dementia or cognitive impairment | meta-analysis | 96,158 | OR 0.93 (95% CI 0.88-0.98); absolute risk reduction 0.39% over 4.1 years |
JAMA
2020 ✓ Peer-reviewed PMID 32427305 |
| Metformin / antidiabetic Medicines | Prevention |
Benefit
whyHeterogeneity was near-total (I-squared 98.9%) and the estimate went to null in people newly diagnosed with diabetes (HR 1.01), which is where prevalent-user bias would be smallest. |
Incident dementia | meta-analysis | 3,463,100 | HR 0.76 (95% CI 0.65-0.91) vs non-users overall; HR 1.01 (0.81-1.27) in newly diagnosed diabetes |
Diabetes, Obesity and Metabolism
2025 ✓ Peer-reviewed PMID 39780315 |